Ori Biotech: Scaling a Cell and Gene Therapy Manufacturing Brand Through Platform Launch and FDA Recognition
Solution
Cell and gene therapies can cure cancers and rare diseases, but manufacturing remains the barrier holding them back, leaving the vast majority of patients without access. Ori Biotech exists to close that gap. Its IRO platform automates, digitises and standardises the most labour-intensive steps of cell and gene therapy (CGT) manufacturing, reducing cost, increasing throughput and cutting batch failures.
SomX has worked with Ori across a sustained growth period, from early audience building through to the commercial launch of IRO and the recognition that followed. The brief has evolved with the company, but the core need has stayed constant: communications that match the ambition of the science and position Ori as the category leader in CGT manufacturing.
Content strategy and social growth
We run Ori's content programme across LinkedIn and owned channels, building an audience of therapy developers, CDMOs, investors and the wider CGT community. The content connects technical capability to commercial and clinical outcomes: platform features, partner milestones, conference activity and the manufacturing challenges IRO is built to solve.
Launch and milestone communications
We have supported Ori through landmark moments, including the commercial launch of IRO at the International Society for Cell & Gene Therapy (ISCT) conference and its FDA Advanced Manufacturing Technology (AMT) designation, one of the first technologies to receive it. Each milestone is built into a coordinated content, social and design programme so it reaches the right audiences and keeps working long after the announcement.
Video and multimedia production
We produce video and multimedia that explain a complex platform clearly, from platform films to campaign assets, used across launches, conferences and Ori's digital channels.
Website and ongoing support
We support Ori's website on a continuing basis, keeping platform, partner, events and IP content current as the company grows, alongside design and campaign work that maintains a consistent brand as IRO scales.
Results
- A communications programme that scaled with the company: from early audience building through the commercial launch of the IRO platform and beyond.
- Milestone moments amplified: coordinated content, social, video and design around the IRO launch at ISCT and the platform's FDA Advanced Manufacturing Technology designation, one of the first technologies to receive it.
- An engaged industry audience: a LinkedIn and owned-channel presence built around therapy developers, CDMOs, investors and the CGT community, with engagement consistently above sector benchmarks (>19k followers built from scratch).
- Category positioning: Ori established as a leading voice in cell and gene therapy manufacturing, with communications that connect platform capability to real-world clinical and commercial impact.
- A continuing partnership: an ongoing retainer spanning content, social, video, website and design, adapting as Ori's platform and partner base grow.
Reflection
Ori Biotech is solving one of the hardest problems in modern medicine: making advanced therapies manufacturable at scale. Communicating that to a technical, sceptical audience takes a partner who understands the science and the commercial stakes. Across a multi-year relationship, we have helped Ori turn platform launches, partner milestones and regulatory recognition into a consistent industry presence, positioning the company as a category leader in cell and gene therapy manufacturing. As IRO continues to scale, the work continues to grow with it.
